# Gastroesophageal Reflux Disease and Barrett Esophagus

## Pathophysiology of GERD

### Antireflux Barrier Dysfunction

The antireflux barrier is a complex anatomical and physiological structure whose disruption underlies the development of gastroesophageal reflux disease. Lower esophageal sphincter (LES) hypotension, defined as a resting pressure below 10 mmHg, is associated with severe reflux and represents a fundamental mechanical failure of the barrier. However, the most common mechanism of reflux in patients with mild-to-moderate GERD is transient LES relaxations (TLESRs), which are vagally mediated events triggered by gastric distension and are distinct from swallow-induced LES relaxation.

Hiatal hernia plays a critical role in GERD pathophysiology through several mechanisms: it disrupts the reinforcement provided by the crural diaphragm, creates an acid pocket that sits above the diaphragm rather than below it, and impairs esophageal acid clearance. The vast majority of hiatal hernias are Type I (sliding), accounting for approximately 95% of cases, which separate the LES from the crural diaphragm. Types II through IV (paraesophageal) are less commonly associated with reflux disease.

### Esophageal Defense Mechanisms

The esophagus possesses a multilayered defense system against refluxate injury. Pre-epithelial defenses include saliva, which contains bicarbonate and epidermal growth factor, as well as the mucus layer that coats the esophageal surface. Epithelial defenses comprise tight junctions between squamous cells, intercellular spaces (which become dilated in non-erosive reflux disease), and bicarbonate transport mechanisms. Post-epithelial defenses rely on mucosal blood flow to neutralize acid and support tissue repair. Esophageal clearance through both primary and secondary peristalsis, augmented by gravity in the upright position, constitutes an additional protective mechanism.

### Acid Pocket Concept

The acid pocket is an unbuffered pool of highly acidic gastric juice that accumulates at the gastric cardia in the postprandial period. In patients with a hiatal hernia, this acid pocket sits above the level of the diaphragm, placing it in direct contact with the squamous epithelium of the distal esophagus. This concept provides the rationale for alginate-based therapies such as Gaviscon Advance, which form a physical raft that displaces the acid pocket and provides a mechanical barrier against reflux.

## Clinical Presentation and Diagnosis

### Typical Symptoms

Heartburn and regurgitation are the typical symptoms of GERD. In patients under 40 to 50 years of age who lack alarm features, these symptoms are sufficient to justify an empiric trial of proton pump inhibitor therapy without further diagnostic testing. It is important to recognize, however, that a positive response to PPI therapy supports but does not definitively confirm a diagnosis of GERD, as a placebo response rate of up to 40% has been documented.

### Atypical/Extraesophageal Syndromes

Chronic cough, laryngitis, asthma, and dental erosions are recognized extraesophageal syndromes that may be attributable to GERD. However, the attribution of these symptoms to reflux requires the concomitant presence of typical GERD symptoms. Laryngeal findings such as posterior laryngitis and vocal cord edema are nonspecific and have been documented in more than 50% of healthy control subjects. Clinicians should not initiate empiric PPI therapy for isolated extraesophageal symptoms without objective evidence of pathologic reflux.

### Alarm Features Requiring EGD

Alarm features that mandate upper endoscopy include dysphagia, odynophagia, unintentional weight loss, gastrointestinal bleeding, iron deficiency anemia, and persistent vomiting. The age threshold for initial endoscopy varies by guideline, with the ACG recommending upper endoscopy in males over 50 years of age with chronic GERD lasting more than 5 years who have additional Barrett esophagus risk factors.

### Diagnostic Testing Hierarchy (Lyon Consensus 2.0, 2024)

The Lyon Consensus 2.0, published in 2024, provides a standardized framework for the objective diagnosis of GERD. Upper endoscopy serves as the initial invasive evaluation, with mucosal injury graded by the Los Angeles (LA) classification. LA Grade A esophagitis is considered non-conclusive for GERD, Grade B is borderline, and Grades C and D are conclusive evidence of pathologic reflux.

| LA Grade | Description | GERD Conclusion (Lyon 2.0) |
|---|---|---|
| A | Mucosal break(s) ≤5 mm, not extending between tops of mucosal folds | Non-conclusive |
| B | Mucosal break(s) >5 mm, not extending between tops of mucosal folds | Borderline |
| C | Mucosal break(s) extending between tops of ≥2 mucosal folds but <75% of circumference | Conclusive |
| D | Mucosal break(s) involving ≥75% of esophageal circumference | Conclusive |

Ambulatory pH monitoring represents the gold standard for objective GERD diagnosis. The wireless Bravo capsule allows 48 to 96 hours of recording and can be performed on or off PPI therapy, though off-PPI testing is preferred. Catheter-based pH-impedance monitoring provides 24-hour recording and is the preferred modality when performed off PPI therapy, with a 10 to 14 day washout period required. The impedance component adds the ability to detect non-acid and weakly acid reflux episodes.

Key diagnostic metrics include acid exposure time (AET), with values below 4% considered normal, 4 to 6% inconclusive, and above 6% abnormal. On impedance testing, more than 80 total reflux episodes indicates an abnormal study, while fewer than 40 is considered normal. Adjunctive measures include mean nocturnal baseline impedance (MNBI), where values below 1500 ohms suggest impaired mucosal integrity, and the post-reflux swallow-induced peristaltic wave (PSPW) index, where values below 50% indicate impaired esophageal chemical clearance.

| Metric | Normal | Inconclusive | Abnormal |
|---|---|---|---|
| Acid Exposure Time (AET) | <4% | 4–6% | >6% |
| Total Reflux Episodes (impedance) | <40 | 40–80 | >80 |
| Mean Nocturnal Baseline Impedance (MNBI) | >2500 ohms | — | <1500 ohms |
| PSPW Index | >61% | — | <50% |

<image>A comprehensive diagnostic algorithm flowchart for GERD evaluation based on Lyon Consensus 2.0. Start with "Typical GERD symptoms" at the top, branching to "Alarm features present?" (yes leads to EGD; no leads to empiric PPI trial 8 weeks). After PPI trial, branch into "Symptom response" and "No response." For non-responders: optimize PPI, then proceed to EGD off PPI followed by ambulatory reflux monitoring off PPI. Show decision nodes for LA Grade classification (A = inconclusive, B = borderline, C-D = conclusive GERD). Include pH-impedance metrics in a sidebar box: AET thresholds (<4%, 4-6%, >6%), reflux episode count, MNBI, and PSPW index with their normal/abnormal cutoffs. Use blue boxes for diagnostic tests, green for conclusive GERD, yellow for borderline, red for non-GERD. Include arrows showing the flow and decision points clearly labeled.</image>

## GERD Management

### Lifestyle Modifications

Weight loss carries the strongest evidence among lifestyle modifications, with a BMI reduction of 3.5 points associated with significant symptom improvement. Elevation of the head of the bed by 6 to 8 inches (using bed risers or a wedge, not merely extra pillows) reduces nocturnal esophageal acid exposure. Patients should avoid recumbency for 2 to 3 hours after meals. Selective food avoidance based on individual triggers — including coffee, chocolate, spicy foods, and alcohol — may be beneficial, although the evidence for universal dietary restrictions is variable. Smoking cessation is recommended, as smoking decreases LES pressure and impairs esophageal clearance.

### Pharmacotherapy

Proton pump inhibitors remain the mainstay of GERD treatment. All PPIs demonstrate equivalent efficacy at standard doses, which include omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg, esomeprazole 40 mg, and dexlansoprazole 30 mg.

| PPI | Standard Dose | Notes |
|---|---|---|
| Omeprazole | 20 mg daily | Reference PPI |
| Lansoprazole | 30 mg daily | |
| Pantoprazole | 40 mg daily | Least CYP2C19 interaction |
| Rabeprazole | 20 mg daily | Least CYP2C19 dependent |
| Esomeprazole | 40 mg daily | S-isomer of omeprazole |
| Dexlansoprazole | 30 mg daily | Dual delayed-release |
| Vonoprazan (PCAB) | 20 mg daily | Not affected by CYP2C19; FDA-approved 2023  |  PPIs should be taken 30 to 60 minutes before the first meal of the day for optimal acid suppression. CYP2C19 polymorphisms affect PPI metabolism, with poor metabolizers achieving better acid suppression and rapid metabolizers potentially requiring dose escalation. Vonoprazan, a potassium-competitive acid blocker (PCAB) administered at 20 mg daily, was FDA-approved in 2023 for erosive esophagitis. It offers faster onset of action and is not affected by CYP2C19 polymorphisms. |

H2 receptor antagonists serve an adjunctive role, particularly for nocturnal acid breakthrough. Famotidine at 20 to 40 mg at bedtime is the most commonly used agent, though tachyphylaxis limits its long-term efficacy. Alginate-based therapy forms a physical raft atop the acid pocket and is useful for postprandial symptom relief. Baclofen, a GABA-B agonist at doses of 5 to 20 mg three times daily, reduces TLESRs by 40 to 60% but is limited by central nervous system side effects including somnolence and dizziness.

### PPI Safety — Evidence Review

The safety profile of long-term PPI use has been extensively studied. The association with bone fracture risk is modest, with a number needed to harm exceeding 1000 per year, and adequate calcium and vitamin D intake should be ensured. The relative risk of C. difficile infection is approximately 1.7, which is clinically relevant primarily in hospitalized or antibiotic-exposed patients. Observational associations with chronic kidney disease are likely confounded and do not require dose adjustment. Hypomagnesemia is rare, occurring in fewer than 1% of patients, but magnesium levels should be monitored in patients on concurrent diuretics or those developing symptoms. Fundic gland polyps are benign and regress after PPI discontinuation. The association with gastric cancer is confounded by H. pylori status, with no proven causal link in H. pylori-negative patients. The overarching principle is that benefits outweigh risks when GERD has been objectively confirmed, but indefinite PPI therapy without a clear indication should be avoided.

### Antireflux Surgery and Endoscopic Therapies

Laparoscopic Nissen fundoplication creates a 360-degree wrap around the distal esophagus and represents the gold standard surgical intervention, with 85 to 90% patient satisfaction at 5 years. Dysphagia occurs in 5 to 10% of patients, and gas-bloat syndrome in 10 to 15%. Toupet fundoplication creates a 270-degree posterior partial wrap and is preferred when esophageal peristalsis is weak. Magnetic sphincter augmentation (LINX device) employs a ring of titanium beads with magnetic cores and has shown outcomes comparable to Nissen at 5 years with lower rates of gas-bloat. LINX is contraindicated in patients with severe esophagitis, Barrett esophagus, or large hiatal hernia exceeding 3 cm.

Transoral incisionless fundoplication (TIF) using the EsophyX device creates a partial fundoplication endoscopically and is suitable for patients with small hiatal hernia below 2 cm and Hill grade I-II valve anatomy, though efficacy compared to sham is modest. Roux-en-Y gastric bypass is the preferred antireflux procedure in obese patients with a BMI above 35, as it simultaneously addresses both obesity and reflux disease.

## Barrett Esophagus

### Definition and Epidemiology

Barrett esophagus is defined as the replacement of the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia containing goblet cells. Diagnosis requires both endoscopic identification of columnar-appearing mucosa above the gastroesophageal junction and histologic confirmation of intestinal metaplasia on biopsy, as per AGA and ACG guidelines.

The prevalence of Barrett esophagus is estimated at 5 to 15% of patients with chronic GERD and 1 to 2% of the general population. Risk factors include chronic GERD exceeding 5 years in duration, male sex (with an 8:1 male-to-female ratio), age over 50, Caucasian race, central obesity, smoking, and a family history of Barrett esophagus or esophageal adenocarcinoma. Protective factors include H. pylori infection (particularly CagA-positive strains) and regular use of NSAIDs or aspirin.

### Prague Classification

The Prague Classification provides a standardized method for describing the extent of Barrett esophagus using two measurements: C (circumferential extent) and M (maximal extent, including tongues). For example, a C3M5 designation indicates 3 cm of circumferential Barrett mucosa with tongues extending to a maximal length of 5 cm. Short-segment Barrett esophagus is defined as less than 3 cm, while long-segment Barrett esophagus is 3 cm or greater. Islands and tongues extending above the circumferential segment are recorded separately.

### Dysplasia Grading

Dysplasia in Barrett esophagus is graded as negative for dysplasia, indefinite for dysplasia, low-grade dysplasia (LGD), or high-grade dysplasia (HGD). Confirmation of any dysplasia diagnosis by an expert GI pathologist is required before committing to therapy, as interobserver variability is notably high, particularly for the diagnosis of low-grade dysplasia.

<image>An endoscopic view illustration showing four panels of Barrett esophagus at different stages. Panel 1: Non-dysplastic Barrett with salmon-colored tongues extending above the GEJ with clear squamocolumnar junction (Z-line) irregular, labeled with Prague classification C2M4. Panel 2: Barrett with low-grade dysplasia showing subtle mucosal irregularity with NBI (narrow-band imaging) view showing irregular mucosal pattern. Panel 3: High-grade dysplasia with nodular area visible on white light, and NBI showing irregular surface and vascular patterns (absent regular pit pattern). Panel 4: Early esophageal adenocarcinoma (Paris 0-IIa lesion) with a raised nodule, shown in both white light and NBI views side by side. Include labels for each panel indicating the diagnosis and key endoscopic features. Use realistic mucosal color tones: salmon-pink for Barrett mucosa, pale pink for normal squamous, darker red-brown for dysplastic areas.</image>

### Surveillance Protocols (ACG 2022)

For non-dysplastic Barrett esophagus, surveillance endoscopy with 4-quadrant biopsies obtained every 2 cm along the Barrett segment (the Seattle protocol) is recommended at 3 to 5 year intervals. When biopsies are indefinite for dysplasia, PPI therapy should be optimized for 12 weeks followed by repeat endoscopy; if the finding persists, a 12-month surveillance interval is appropriate. Confirmed low-grade dysplasia, validated by an expert pathologist, is preferably managed with endoscopic eradication therapy (EET), though surveillance every 6 to 12 months is acceptable if EET is deferred. High-grade dysplasia warrants EET with radiofrequency ablation, with or without endoscopic mucosal resection of any visible lesions. Intramucosal carcinoma (T1a) should be treated with EMR or endoscopic submucosal dissection (ESD) of the visible lesion followed by RFA of residual flat Barrett.

| Dysplasia Grade | Surveillance Interval | Preferred Management |
|---|---|---|
| Non-dysplastic | Every 3–5 years | Seattle protocol biopsies; PPI therapy |
| Indefinite for dysplasia | Optimize PPI × 12 weeks, repeat EGD; then every 12 months | Maximize acid suppression; repeat biopsies |
| Low-grade dysplasia (confirmed) | Every 6–12 months if EET deferred | EET preferred (RFA ± EMR) |
| High-grade dysplasia | EET recommended | RFA ± EMR/ESD of visible lesions |
| Intramucosal carcinoma (T1a) | EET recommended | EMR/ESD of lesion + RFA of residual Barrett  |  When margins are clear, there is no lymphovascular invasion, and the tumor is well-differentiated, the risk of lymph node metastasis is low, supporting an endoscopic approach. |

### Endoscopic Eradication Therapy (EET)

Endoscopic mucosal resection (EMR) is indicated for visible lesions such as nodules classified by the Paris system as 0-IIa, 0-IIb, or 0-IIc. Both band-ligation and cap-assisted techniques are utilized, and piecemeal resection is acceptable for benign-appearing lesions. Endoscopic submucosal dissection (ESD) achieves en bloc resection of larger lesions and is preferred for lesions exceeding 2 cm or those with suspected submucosal invasion, as accurate histologic staging depends on intact specimen architecture. ESD is technically demanding and requires advanced endoscopic training.

Radiofrequency ablation (RFA) is applied to flat Barrett mucosa after resection of visible lesions, using either the HALO360 circumferential or HALO90 focal ablation devices. Complete eradication of intestinal metaplasia (CE-IM) is achieved in 78 to 92% of patients, and complete eradication of dysplasia (CE-D) in 90 to 95%. Cryotherapy using spray application of liquid nitrogen or carbon dioxide serves as an alternative for residual or recurrent Barrett after RFA and as a first-line option for flat dysplasia.

Post-EET surveillance is essential, as recurrence rates of 8 to 15% per year have been documented. Continued surveillance is required even after achieving complete eradication of intestinal metaplasia, with endoscopy recommended every 3 to 6 months in the first year and annually thereafter. Lifelong PPI therapy is also required.

### Advanced Imaging for Barrett

Narrow-band imaging (NBI) enhances surface and vascular pattern visualization and is used with the BING criteria for dysplasia detection. Confocal laser endomicroscopy provides real-time histologic assessment but remains primarily a research tool. Volumetric laser endomicroscopy (VLE/OCT) offers subsurface imaging capable of detecting buried Barrett beneath the neosquamous epithelium. AI-assisted detection systems for real-time dysplasia identification are currently in clinical trials and represent a promising advance in Barrett surveillance.

### Chemoprevention

PPI therapy has been shown to reduce progression to dysplasia and esophageal adenocarcinoma, with odds ratios ranging from 0.29 to 0.47. The AspECT trial demonstrated that high-dose PPI combined with aspirin was superior to low-dose PPI alone in reducing a composite endpoint of mortality, esophageal adenocarcinoma, and high-grade dysplasia. However, aspirin is not a standard recommendation for chemoprevention given the associated bleeding risk. Observational data suggest a 40% risk reduction with statin use, though no randomized controlled trial has confirmed this benefit.

## Esophageal Adenocarcinoma Staging Considerations

Accurate staging of early esophageal adenocarcinoma arising in Barrett esophagus is critical for guiding therapy. T1a tumors confined to the intramucosal layer carry a lymph node metastasis risk of less than 2%, making endoscopic therapy appropriate. T1b tumors invading the submucosa carry a significantly higher lymph node metastasis risk of 10 to 30%, which varies substantially depending on the depth of submucosal invasion (sm1 vs sm2 vs sm3). Surgery is generally recommended for tumors penetrating to the sm2 or sm3 level. Features that increase lymph node risk even in T1a lesions include poor differentiation, lymphovascular invasion, and tumor size exceeding 2 cm.

| Stage | Depth of Invasion | LN Metastasis Risk | Recommended Management |
|---|---|---|---|
| T1a | Intramucosal (lamina propria / muscularis mucosae) | <2% | Endoscopic therapy (EMR/ESD + RFA) |
| T1b-sm1 | Superficial submucosa | 8–12% | Consider surgery; endoscopic if favorable features |
| T1b-sm2/3 | Deep submucosa | 20–30% | Surgery recommended |
| T2 | Muscularis propria | >40% | Surgery + neoadjuvant therapy |

<image>A staging diagram showing cross-sectional layers of the esophageal wall with Barrett-related neoplasia progression. Show five vertical layers clearly labeled from lumen outward: epithelium, lamina propria, muscularis mucosae (note the doubled muscularis mucosae unique to Barrett), submucosa (divided into sm1, sm2, sm3 thirds), and muscularis propria. Overlay arrows showing: Tis (carcinoma in situ, confined to epithelium), T1a (invades through lamina propria to muscularis mucosae), T1b-sm1 (superficial submucosa), T1b-sm2/3 (deep submucosa), T2 (muscularis propria). On the right side, show a risk bar for lymph node metastasis: <2% for T1a, 8-12% for T1b-sm1, 20-30% for T1b-sm2/3, >40% for T2. Include treatment recommendation labels: "Endoscopic therapy" for T1a, "Consider surgery" for T1b-sm1, "Surgery recommended" for T1b-sm2 and deeper. Use color gradient from green (low risk) to red (high risk) for the metastasis bar.</image>

## Key Clinical Pearls

- Lyon Consensus 2.0: LA Grade C-D esophagitis or AET >6% are conclusive for GERD; Grade A is NOT diagnostic
- Always confirm dysplasia in Barrett with a second expert GI pathologist before committing to therapy
- Visible lesions in Barrett must be resected (EMR/ESD) BEFORE ablation for accurate staging
- Post-EET recurrence is common (8-15%/year) — lifelong surveillance is mandatory
- Vonoprazan (PCAB) offers an alternative for CYP2C19 rapid metabolizers or PPI-refractory patients
- PPI therapy should be objectively justified; discontinue if no confirmed GERD on testing
- LINX is contraindicated in Barrett esophagus
- Short-segment Barrett (<3 cm, non-dysplastic) has very low annual cancer risk (~0.1-0.3%/year)

## References
1. Gyawali CP, et al. Updates to the Lyon Consensus for diagnosing gastroesophageal reflux disease. *Gut*. 2024;73(2):361-371.
2. Shaheen NJ, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol*. 2022;117(4):559-587.
3. Katz PO, et al. ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2022;117(1):27-56.
4. Jankowski JAZ, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. *Lancet*. 2018;392(10145):400-408.
5. Shaheen NJ, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med*. 2009;360(22):2277-2288.